{"id":"isoniazid-for-9-months","safety":{"commonSideEffects":[{"rate":"1-2%","effect":"Peripheral neuropathy"},{"rate":"1-3%","effect":"Hepatotoxicity"},{"rate":"<1%","effect":"Hypersensitivity reactions"},{"rate":"<1%","effect":"Drug-induced lupus"},{"rate":"1-2%","effect":"Nausea and vomiting"},{"rate":"<1%","effect":"Arthralgia"}]},"_chembl":{"chemblId":"CHEMBL64","moleculeType":"Small molecule","molecularWeight":"137.14"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Isoniazid is a prodrug that requires activation by the mycobacterial enzyme catalase-peroxidase (KatG) to form an isonicotinoyl radical. This activated form binds to mycobacterial enoyl-ACP reductase (InhA), inhibiting the synthesis of mycolic acids that are critical structural components of the mycobacterial cell wall. This leads to cell wall disruption and bactericidal activity against actively dividing M. tuberculosis.","oneSentence":"Isoniazid inhibits mycobacterial cell wall synthesis by blocking mycolic acid production, which is essential for Mycobacterium tuberculosis survival.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:17:20.587Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Tuberculosis (TB) - as part of standard 9-month combination therapy"},{"name":"Latent tuberculosis infection (LTBI) prophylaxis"}]},"trialDetails":[{"nctId":"NCT06153069","phase":"PHASE4","title":"Asymptomatic TB With Innovative Modified Short-course Regimens","status":"RECRUITING","sponsor":"Huashan Hospital","startDate":"2025-11-21","conditions":"Tuberculosis","enrollment":426},{"nctId":"NCT05383742","phase":"PHASE2","title":"Trial of a Six-Month Regimen of High-Dose Rifampicin, High-Dose Isoniazid, Linezolid, and Pyrazinamide Versus a Standard Nine-Month Regimen for the Treatment of Adults and Adolescents With Tuberculous Meningitis","status":"RECRUITING","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2023-12-07","conditions":"Tuberculous Meningitis","enrollment":330},{"nctId":"NCT06905522","phase":"PHASE3","title":"A PAN-USR TB Multi-Center Trial","status":"RECRUITING","sponsor":"Shenzhen Third People's Hospital","startDate":"2025-06-18","conditions":"Pulmonary Tuberculosis","enrollment":610},{"nctId":"NCT07129629","phase":"PHASE2","title":"Short-Course Regimen With Bedaquiline, Moxifloxacin and Pyrazinamide for Early Bactericidal Activity in Drug-Susceptible Tuberculosis","status":"NOT_YET_RECRUITING","sponsor":"Shanghai Pulmonary Hospital, Shanghai, China","startDate":"2025-08-20","conditions":"Tuberculosis, Pulmonary, Drug-Susceptible Pulmonary Tuberculosis","enrollment":45},{"nctId":"NCT07076225","phase":"PHASE3","title":"Ultra-Short Regimen for Elderly DS-TB","status":"NOT_YET_RECRUITING","sponsor":"Shenzhen Third People's Hospital","startDate":"2025-07-25","conditions":"Pulmonary Tuberculosis","enrollment":300},{"nctId":"NCT06874725","phase":"PHASE4","title":"Latent Tuberculosis in Type 2 Diabetes","status":"ACTIVE_NOT_RECRUITING","sponsor":"Taichung Veterans General Hospital","startDate":"2018-04-18","conditions":"Latent Tuberculosis Infection","enrollment":552},{"nctId":"NCT05971602","phase":"PHASE2","title":"Efficacy and Safety Evaluation of Two to Four Months of Treatment With the Combination Regimens of DBOS and PBOS in Adults With Pulmonary Tuberculosis","status":"TERMINATED","sponsor":"Gates Medical Research Institute","startDate":"2023-07-26","conditions":"Pulmonary Tuberculosis","enrollment":93},{"nctId":"NCT05005637","phase":"PHASE2","title":"The Effectivity of Anti Tuberculosis Therapy in Idiopathic Uveitis with Positive IGRA","status":"COMPLETED","sponsor":"Fakultas Kedokteran Universitas Indonesia","startDate":"2021-08-27","conditions":"Tuberculous Uveitis","enrollment":78},{"nctId":"NCT02410772","phase":"PHASE3","title":"TBTC Study 31: Rifapentine-containing Tuberculosis Treatment Shortening Regimens","status":"COMPLETED","sponsor":"Centers for Disease Control and Prevention","startDate":"2016-01-25","conditions":"Tuberculosis","enrollment":2516},{"nctId":"NCT04062201","phase":"PHASE3","title":"Building Evidence for Advancing New Treatment for Rifampicin Resistant Tuberculosis (RR-TB) Comparing a Short Course of Treatment (Containing Bedaquiline, Delamanid and Linezolid) With the Current South African Standard of Care","status":"COMPLETED","sponsor":"Wits Health Consortium (Pty) Ltd","startDate":"2019-08-22","conditions":"Tuberculosis, Pre-XDR-TB, Extensively Drug-Resistant Tuberculosis","enrollment":402},{"nctId":"NCT00023452","phase":"PHASE3","title":"Three Months of Weekly Rifapentine and Isoniazid for M. Tuberculosis Infection","status":"COMPLETED","sponsor":"Centers for Disease Control and Prevention","startDate":"2001-06","conditions":"Tuberculosis","enrollment":8053},{"nctId":"NCT06526039","phase":"PHASE3","title":"A Short Regimen for Rifampicin-resistant Isoniazid-susceptible TB","status":"NOT_YET_RECRUITING","sponsor":"Taipei Medical University WanFang Hospital","startDate":"2024-07","conditions":"Tuberculosis, Pulmonary","enrollment":100},{"nctId":"NCT04856644","phase":"PHASE3","title":"Evaluation of the Efficacy and Safety of a 4-month Daily Regimen (2HZPM/2HPM) for Treatment of Pulmonary TB","status":"ACTIVE_NOT_RECRUITING","sponsor":"Kaohsiung Veterans General Hospital.","startDate":"2020-01-01","conditions":"Tuberculosis, Pulmonary","enrollment":333},{"nctId":"NCT03338621","phase":"PHASE2, PHASE3","title":"Trial to Evaluate the Efficacy, Safety and Tolerability of BPaMZ in Drug-Sensitive (DS-TB) Adult Patients and Drug-Resistant (DR-TB) Adult Patients","status":"COMPLETED","sponsor":"Global Alliance for TB Drug Development","startDate":"2018-07-30","conditions":"Tuberculosis, Pulmonary, Tuberculosis, Multidrug-Resistant, Tuberculosis, MDR","enrollment":455},{"nctId":"NCT04694586","phase":"PHASE2","title":"Drug Exposure and Safety of a Shorter Tuberculosis Treatment Based on High-Dose Rifampicin and Pyrazinamide","status":"SUSPENDED","sponsor":"University Hospital, Linkoeping","startDate":"2022-11-30","conditions":"Tuberculosis, Pulmonary","enrollment":40},{"nctId":"NCT05454345","phase":"PHASE3","title":"Sitafloxacin-containing Regimens for Shortening Tuberculosis Treatment","status":"NOT_YET_RECRUITING","sponsor":"First Affiliated Hospital of Zhejiang University","startDate":"2022-10-01","conditions":"Tuberculosis, Pulmonary","enrollment":620},{"nctId":"NCT02454205","phase":"PHASE2, PHASE3","title":"An Open-label RCT to Evaluate a New Treatment Regimen for Patients With Multi-drug Resistant Tuberculosis","status":"COMPLETED","sponsor":"University of Cape Town","startDate":"2015-11-12","conditions":"Tuberculosis, Multidrug Resistant Tuberculosis, Extensively-drug Resistant Tuberculosis","enrollment":154},{"nctId":"NCT03787940","phase":"NA","title":"Optimizing Antituberculosis Therapy in Adults With Tuberculous Meningitis","status":"UNKNOWN","sponsor":"Beijing Chest Hospital","startDate":"2019-03-04","conditions":"Tuberculous Meningitis","enrollment":676},{"nctId":"NCT00128206","phase":"PHASE3","title":"Treatment of Latent TB Infection for Jailed Persons","status":"COMPLETED","sponsor":"University of California, San Francisco","startDate":"2004-11","conditions":"Tuberculosis","enrollment":364},{"nctId":"NCT02342886","phase":"PHASE3","title":"Shortening Treatment by Advancing Novel Drugs","status":"COMPLETED","sponsor":"Global Alliance for TB Drug Development","startDate":"2015-02","conditions":"Tuberculosis, Pulmonary, Drug Sensitive, Tuberculosis, Pulmonary, Multi Drug-resistant","enrollment":284},{"nctId":"NCT00931736","phase":"PHASE3","title":"Randomized Clinical Trial Comparing 4RIF vs. 9INH for LTBI Treatment-effectiveness","status":"COMPLETED","sponsor":"McGill University","startDate":"2009-08","conditions":"Latent Tuberculosis Infection","enrollment":6031},{"nctId":"NCT00170209","phase":"PHASE3","title":"Rifampin Versus Isoniazid for the Treatment of Latent Tuberculosis Infection in Children (P4v9)","status":"COMPLETED","sponsor":"McGill University","startDate":"2011-08","conditions":"Latent Tuberculosis Infection","enrollment":844},{"nctId":"NCT03312647","phase":"","title":"Adverse Drug Reactions to Anti-TB Drugs in the Treatment of Latent Tuberculosis Infection","status":"UNKNOWN","sponsor":"Hanyang University","startDate":"2017-06-19","conditions":"Latent Tuberculosis Infection","enrollment":1000},{"nctId":"NCT02975570","phase":"PHASE3","title":"Efficacy and Tolerability of Delamanid, Linezolid, Pyrazinamide and Levofloxacin","status":"WITHDRAWN","sponsor":"Boston University","startDate":"2017-08","conditions":"Tuberculosis Multi Drug Resistant Active","enrollment":""},{"nctId":"NCT03230409","phase":"NA","title":"Impact of Nursing Interventions on Adherence to Treatment With Anti-tuberculosis Drugs in Children and Adolescents","status":"COMPLETED","sponsor":"Hospital Sant Joan de Deu","startDate":"2014-01-01","conditions":"Tuberculosis","enrollment":359},{"nctId":"NCT00864383","phase":"PHASE3","title":"Controlled Comparison of Two Moxifloxacin Containing Treatment Shortening Regimens in Pulmonary Tuberculosis","status":"COMPLETED","sponsor":"Global Alliance for TB Drug Development","startDate":"2008-01","conditions":"Pulmonary Tuberculosis","enrollment":1931},{"nctId":"NCT02208427","phase":"PHASE3","title":"Toward a Safe and Reachable Preventive Therapy for LTBI: a Multicenter Randomized Controlled Study in Taiwan","status":"UNKNOWN","sponsor":"National Taiwan University Hospital","startDate":"2014-08","conditions":"Latent Tuberculosis Infection","enrollment":283},{"nctId":"NCT02496572","phase":"","title":"Effectiveness of a Simplified Short Regimen for Multidrug Resistant Tuberculosis in Uzbekistan","status":"UNKNOWN","sponsor":"Medecins Sans Frontieres, Netherlands","startDate":"2013-09","conditions":"Multidrug Resistant Tuberculosis","enrollment":110},{"nctId":"NCT02331823","phase":"PHASE4","title":"Research on New Regimens for Retreatment Pulmonary Tuberculosis","status":"UNKNOWN","sponsor":"Shanghai Pulmonary Hospital, Shanghai, China","startDate":"2013-06","conditions":"Reinfection Pulmonary Tuberculosis","enrollment":864},{"nctId":"NCT01761201","phase":"PHASE3","title":"\"Efficacy and Safety of Levofloxacin vs Isoniazid in Latent Tuberculosis Infection in Liver Transplant Patients\".","status":"TERMINATED","sponsor":"Fundación Pública Andaluza para la gestión de la Investigación en Sevilla","startDate":"2012-01","conditions":"Latent Tuberculosis Infection, Infection in Solid Organ Transplant Recipients","enrollment":68},{"nctId":"NCT01677871","phase":"NA","title":"Efficacy and Safety of Modified Anti-tubercular Regimens in Treatment of Tuberculosis in Patients With Underlying Compensated and Decompensated Chronic Liver Disease","status":"UNKNOWN","sponsor":"Institute of Liver and Biliary Sciences, India","startDate":"2012-09","conditions":"Chronic Liver Disease With Tuberclosis","enrollment":120},{"nctId":"NCT01087190","phase":"NA","title":"Isoniazid (INH) Treatment Based on ELISPOT Assay","status":"COMPLETED","sponsor":"Asan Medical Center","startDate":"2010-06","conditions":"Kidney Transplant Recipient","enrollment":831},{"nctId":"NCT01398618","phase":"PHASE3","title":"Comparing Two Preventive Regimens for Latent Tuberculosis Infection (LTBI)","status":"UNKNOWN","sponsor":"National Taiwan University Hospital","startDate":"2011-05","conditions":"Latent Tuberculosis Infection","enrollment":300}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":133,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Isoniazid"],"phase":"phase_3","status":"active","brandName":"Isoniazid for 9 months","genericName":"Isoniazid for 9 months","companyName":"National Taiwan University Hospital","companyId":"national-taiwan-university-hospital","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Isoniazid inhibits mycobacterial cell wall synthesis by blocking mycolic acid production, which is essential for Mycobacterium tuberculosis survival. Used for Tuberculosis (TB) - as part of standard 9-month combination therapy, Latent tuberculosis infection (LTBI) prophylaxis.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}